Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice
- Himanshu Garg†1, 2Email author,
- Anjali Joshi†1, 2,
- Chunting Ye1,
- Premlata Shankar1 and
- N Manjunath1Email author
© Garg et al; licensee BioMed Central Ltd. 2011
Received: 12 January 2011
Accepted: 21 January 2011
Published: 21 January 2011
The mechanism by which HIV infection leads to a selective depletion of CD4 cells leading to immunodeficiency remains highly debated. Whether the loss of CD4 cells is a direct consequence of virus infection or bystander apoptosis of uninfected cells is also uncertain.
We have addressed this issue in the humanized mouse model of HIV infection using a HIV variant with a point mutation in the gp41 region of the Env glycoprotein that alters its fusogenic activity. We demonstrate here that a single amino acid change (V38E) altering the cell-to-cell fusion activity of the Env minimizes CD4 loss in humanized mice without altering viral replication. This differential pathogenesis was associated with a lack of bystander apoptosis induction by V38E virus even in the presence of similar levels of infected cells. Interestingly, immune activation was observed with both WT and V38E infection suggesting that the two phenomena are likely not interdependent in the mouse model.
We conclude that Env fusion activity is one of the determinants of HIV pathogenesis and it may be possible to attenuate HIV by targeting gp41.
HIV infection in humans leads to a selective depletion of CD4+ T cells that culminates in immunodeficiency or AIDS. While it is clear that the loss of CD4+ T cells is initiated by HIV infection, the mechanism behind this phenomenon remains highly debated. CD4 T cell loss can occur due to multiple mechanisms: direct killing of infected cells , indirect killing of uninfected cells , a defect in the capacity for lymphocyte proliferation or turnover or both , and/or an overzealous chronic immune response and immune activation . The contribution of these processes to CD4 depletion in vivo remains incompletely understood. However, the number of infected cells detectable in HIV-infected individuals is much lower than can account for the profound loss of CD4+ T cells seen with disease progression. Furthermore, SIV infection of the natural hosts in the wild show limited CD4 decline despite active viral replication [5, 6], suggesting that virus infection per se does not lead to CD4 T cell destruction. Because of these reasons, it has been proposed that apoptosis of uninfected bystander cells may contribute to the depletion of CD4+ T cells [7–9]. In fact, the majority of T cells undergoing apoptosis in peripheral blood and lymph nodes of HIV patients are uninfected . Moreover, massive apoptosis was predominantly observed in uninfected CD4+ T cells present in lymph nodes, thymus or spleen in animal models, such as rhesus macaques infected by SIV or highly pathogenic SIV/HIV chimeric viruses [11, 12].
Several HIV-1 proteins, such as HIV envelope glycoprotein Env [13–15], Nef [16, 17], Tat [18, 19] and Vpr [20, 21] can induce T cell apoptosis. However, which of these factors are important in vivo is not clear, although cumulative data suggest a major role of Env in cell death of uninfected lymphocytes . Under experimental conditions, Env, either in a soluble  or membrane-bound form [23, 24], can induce the death of uninfected bystander CD4+ T cells. In Macaque models the membrane fusing activity of the Env glycoprotein has been shown to be critical for CD4 loss [25, 26]. However, which mechanism is pertinent for the destruction of CD4 T cells in vivo has not been examined under controlled conditions. We have previously characterized a HIV variant with a single amino acid mutation in the gp41 (V38E) that exhibited deficiency in cell-to-cell fusion activity and apoptosis induction in vitro as well as increased Enfuvirtide resistance . Using this virus as a model system, in this study, we have compared the pathogenicity of WT and V38E mutant in the humanized mice and find that while both viruses replicate to similar levels and induce immune activation, V38E mutant is compromised in its ability to induce a progressive CD4 T cell loss consequent to its failure to induce bystander apoptosis.
Virus Stock and plasmids
Virus stocks were prepared with molecular clones of the WT virus or V38E mutant as described previously . Briefly, virus stocks were prepared by 293T transfection using infectious molecular clones and Ex Gen 500 transfection reagent. Virus supernatant was collected 48h post transfection, cleared of cellular components by centrifugation, aliquoted and stored at -70°C. WT virus contains the Lai ENV in NL4-3 backbone and the mutant V38E was generated by site directed mutagenesis and have been described previously [27, 28]. Virus preparations were quantified using Reverse Transcriptase (RT) activity assay as well as titration in TZMbl indicator cell line (NIH AIDS research and reference reagent program). Enfuvirtide (NIH AIDS research and reference reagent program) resistance was determined in TZMbl cell infection.
In vitro infection and Apoptosis detection
SupT1 cells (NIH AIDS research and reference reagent program) were infected with equal RT activity units of viruses and cultured for indicated times. The cultures were split 1:3 every other day and culture supernatants were harvested for determination of RT activity. Cells were collected at day 3 or day 5 post infection, fixed and permeabilized and stained with anti-p24 RD-1 antibody clone KC57 (Beckman Coulter) for detection of virus infection and with activated caspase indicator, ZVAD-FITC (Promega) for apoptosis. Flow cytometry was performed on the samples on a FACS CANTO-II flow cytometer. Data was analyzed using FACS DIVA software with at least 20,000 events acquired for each sample. At day 3 or 5 postinfection, cells were also assayed for viability using the Cell Titer Glo (Promega) viability assay. Supernatants from the cultures were assayed for virus replication using RT assay.
Virus Replication Assay
Peripheral blood was collected from healthy volunteers at Texas Tech University Health Sciences Center (TTUHSC) under protocol approved by the TTUHSC Institutional Review board. PBMCs were separated from whole blood by Ficoll density centrifugation. CD4+ T cells were isolated using negative selection with immunomagnetic beads (Invitrogen). Naïve CD4+ T cells were activated using 5 μg/ml PHA and 25U/ml IL-2 (NIH AIDS Reference and Reagent Program) for 3 days prior to infection. Equal RT units of virus were used to infect the CD4+ PBMCs and cultured for 18 days. Supernatants collected at different time points were assayed for RT activity to determine virus replication.
Generation of Humanized mice
Humanized BLT mice used in the study were generated as described . Briefly NOD SCID IL2Rγ-/- mice were obtained from Jackson Laboratory (Bar Harbor, ME) and housed at the Texas Tech animal facility as per institutional guidelines. Fetal tissue was obtained from Advanced Bioscience Resources (Alameda, CA). Mice were irradiated with 3gy total body irradiation prior to surgical transplantation of fetal thymus and liver tissue (1-3 mm) under the kidney capsule. CD34+ stem cells were isolated from the fetal liver the same day using positive selection with anti-CD34 coated microbeads (Miltenyi Biotec, Auburn, CA). 5X105 CD34+ cells were injected in the mice IV following tissue implantation. Human cell expansion and repopulation was determined 10-12 weeks post implantation by multicolor flow cytometric analysis by staining of PBMCs with CD45, CD4 and CD8 antibodies (Beckman Coulter). All use of human tissues and animals was as per institutional guidelines and approved by the Institutional Review Board at TTUHSC.
Infection of Humanized mice
BLT mice at 12-14 weeks post reconstitution were infected with 50,000 TCID50 of virus stocks intraperitoneally. Total of four mice per group were infected with either WT or V38E virus. However one mouse in the V38E and WT group was lost at 2 and 4 weeks respectively during bleeding. Data from all 4 mice is included where available. Peripheral blood was collected from the mice by retro orbital bleeding every 2 weeks for a total of 8 weeks. PBMCs collected at each time point were stained for CD45, CD4, CD8, HLADR, and PD-1. At the 8 weeks end point mice were sacrificed and the spleens were collected and divided in half. One half was fixed in neutral buffered formalin for immunohistopathology. The other half was used for isolation of splenocytes and staining as above. In addition to HLADR and PD-1, staining for CCR5 expression was also performed at the 8 week end point.
Formalin fixed tissue was paraffin embedded and sectioned. Antigen retrieval was performed using microwave. Sections were stained with FITC conjugated anti- caspase 3 antibody (Beckman Coulter) and RD-1 conjugated anti-p24 antibody KC57 clone (Beckman Coulter) at 1:200 dilution overnight. After extensive washing the slides were stained with DAPI (Antifade) (Invitrogen) and observed under fluorescence microscopy (Nikon Ti Eclipse microscope). Fluorescent images were collected using NIS image acquisition and analysis software (Nikon). Automated quantitation was performed with NIS software to determine total p24, caspase or DAPI stained cells.
Recovery of virus from PBMCs
DNA was extracted from PBMCs using Qiagen DNA isolation kit. Nested PCR used for amplification of gp41 region has been described by others Aquaro et al . Virus was recovered from PBMCs of infected mice at 8 weeks post infection by coculturing of PHA (5 μg/ml) and IL-2 (25U/ml)-activated PBMCs (5X105 cells) with 106 SupT1 cells. RT activity was determined at different time points and supernatants collected for virus sequencing. Formation of syncytia was recorded on day 10 when virus replication was at the peak.
V38E virus fails to induce bystander apoptosis in SupT1 cells even in the presence of active viral replication
V38E mutant is attenuated in inducing CD4 decline in humanized mice
WT virus infection is characterized by extensive bystander apoptosis in the spleen
V38E mutant replicates in humanized mice without reverting to WT
Both WT and V38E viruses mediate immune activation in CD8 cells
Immune activation correlates with CD4 decline in WT virus but not V38E mutant
CCR5 upregulation in CD8 T cells is similar for WT and V38E infection
While the selective loss of CD4 cells over a prolonged period of HIV infection is quiet clear, the mechanism behind this phenomenon remains elusive. We tested the hypothesis that gp41-induced cell-to-cell fusion activity is involved in HIV pathogenesis using an HIV variant with a point mutation in the gp41 region of Env and the humanized mouse model. Compared to WT virus, CD4 loss and bystander apoptosis were both compromised in the V38E mutant. These studies are indicative that the pathogenesis of HIV maybe partially related to the fusogenic potential of the Env glycoprotein. Incidentally, the V38E mutant is one of the Enfuvirtide resistant mutation associated with immunological benefits in patients undergoing Enfuvirtide therapy [31, 40]. Whether the lack of bystander apoptosis inducing phenotype in the humanized mice has a relevance to clinical benefits remains to be seen.
Among the several hypotheses proposed for CD4 loss, the role of HIV Env mediated bystander cell death is now gaining strength [22, 41]. This is largely due to the fact that Env glycoprotein is expressed on the surface of infected cells, binds to CD4 on bystander cells and can mediate apoptosis . Furthermore, as the depletion of cells in HIV infection is largely restricted to CD4+ T cells and Env binds directly to CD4, a role of Env glycoprotein in further indicated. Although earlier studies suggested that soluble gp120 could induce apoptosis, recent studies point to the importance of membrane expressed Env glycoprotein in bystander apoptosis . The role of gp41 is further strengthened by recent data suggesting that HIV-mediated bystander cell death can be inhibited by gp41 specific fusion inhibitor T20 (Enfuvirtide) . Recent clinical studies have also demonstrated that certain resistant mutants arising in patients undergoing Enfuvirtide therapy are associated with CD4 increase even after virological failure [31, 40]. Furthermore, the reduction of fusogenic activity in Enfuvirtide resistant viruses has been demonstrated by Reeves et al . While binding of Env to CD4 as well as a coreceptor CXCR4/CCR5 are both required for apoptosis induction in vitro, these interactions alone have been shown to be insufficient for apoptosis induction [44, 45]. Using coculture experiments with receptor expressing cells, we and others have recently hypothesized that the fusogenic activity mediated by gp41 is critical for apoptosis induction in vitro[28, 46–49]. Our in vitro data in this study using WT or V38E infected Sup-T1 cells confirms this hypothesis. We find that V38E mutant is incapable of inducing bystander apoptosis in the presence of significant infection and replication in SupT1 cell line. Interestingly bystander apoptosis is seen quiet early in WT infected cultures, suggesting that in fact, a few infected cells can mediate apoptosis of a large number of uninfected bystander cells. Given that the point mutation in gp41 restricts the cell-to-cell fusion capacity of the V38E mutant, while maintaining the virus-cell fusion activity and consequently virus replication, we can state that HIV Env mediated apoptosis is at least in part dependent on Env fusion function. More importantly we can also state that bystander apoptosis is most likely independent of virus replication.
The chronic immune activation and CD4 decline as well as high levels of virus replication seen in the humanized mice makes it a promising model to study HIV pathogenesis [35, 36]. However the mechanism of CD4 loss in this model remained unclear and there is no evidence that CD4 loss in this model is associated with apoptosis induction in bystander cells or otherwise. The differential loss of CD4 cells mediated by WT and V38E virus in the presence of similar levels of viremia is a strong indicator of the role of gp41 in CD4 loss. Our study also addressed the question whether bystander apoptosis was involved in the differential CD4 loss between the viruses. Bystander apoptosis was first recognized by Finkel et al in lymph nodes from HIV infected individuals and SIV infected monkeys . Differential bystander apoptosis has also been demonstrated in the nonpathogenic SIVsm infection in Sooty Mangabeys versus SIVmac infection in Rhesus Macaques [6, 50]. However none of the previous studies provided any mechanistic insights into this phenomenon. The fact that in our study WT virus infection induces extensive bystander apoptosis that is strikingly absent in V38E virus infection is evidence that the fusogenic activity of the Env glycoprotein may play a key role in bystander apoptosis and consequently CD4 decline in vivo.
Another major immunopatholgical change in HIV infection is immune activation  that has also been reported in the humanized mouse model [35, 36, 39]. However the correlation between immune activation and CD4 decline in HIV infection is unclear. Our results show that the immune activation in this model is largely restricted to CD8 T cell over the 8-week period of study similar to recent findings by others [35, 36]. Interestingly immune activation between V38E and WT virus infection was similar even though CD4 decline was limited in V38E infection. Correlation analysis revealed that while in WT infection CD8 immune activation correlates with CD4 decline this was not true for V38E infection. Hence, we were able to dissociate immune activation from CD4 decline in this model of HIV infection. Another question is what exactly mediates immune activation in HIV infection. Compromise of the intestinal epithelial barrier and consequent LPS leakage into circulation has been proposed to mediate immune activation in HIV infection . A recent study by Hofer et al further demonstrated that immune activation in the humanized mouse model is a consequence of failure to clear LPS due to a macrophage dysfunction induced by HIV infection . In the same study, experimental induction of immune activation in the absence of HIV infection failed to induce a CD4 decline, suggesting that immune activation may not be the cause of CD4 decline in agreement with our results in this study. It has also been suggested that immune activation in CD8 cells maybe more closely related to active virus replication since the initiation of HAART therapy and reduction in viral load abrogates immune activation in HIV infected individuals . Recently, stimulation of TLR 7/8 by HIV ssRNA has also been proposed as a mechanism of immune activation induced by HIV infection [52, 53]. Hence it is not surprising that immune activation was seen with the V38E virus as it replicated to similar levels as WT virus.
Although there are apparent differences between the humanized mice and human infections, and though the findings here cannot be directly extrapolated to HIV pathogenesis in humans, we can still appreciate the differential pathogenesis of a point mutant of HIV. While the use of a laboratory adapted X4 (Lai) isolate is also a limitation of our study the major emphasis of our study is on using the Lai WT and V38E mutant as a model system to study the phenomenon of bystander apoptosis. Our study does provide the first direct evidence of bystander apoptosis as the mechanism of CD4 decline in the humanized mouse model. How relevant are these findings to clinical isolates and HIV pathogenesis in humans remains to be determined. Further studies using viruses directly isolated from patients is likely to address these issues. Furthermore it is known that certain mutations in gp120 that regulate CD4 binding also affect Env fusogenicity [9, 54] and in turn could also affect bystander apoptosis in vivo. Hence our study supports the idea that targeting different regions of the Env glycoprotein to select less fusogenic variants may have clinical benefits. This study represents a first step in using the humanized mouse model to study differential pathogenesis of HIV-1 Env variants and opens the door to further investigation using this model system.
We are grateful to the NIH AIDS Research and Reference Reagent Program, for supplying valuable reagents. We would like to thank Dolores Diaz for immunohistopathology. This work was supported by TTUHSC seed grant to HG and NIH grants to NM and PS.
- Gandhi R, Chen B, Straus S, Dale J, Lenardo M, Baltimore D: HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med 1998, 187: 1113-1122. 10.1084/jem.187.7.1113PubMed CentralView ArticlePubMedGoogle Scholar
- Finkel T, Banda N: Indirect mechanisms of HIV pathogenesis: how does HIV kill T cells? Curr Opin Immunol 1994, 6: 605-615. 10.1016/0952-7915(94)90149-XView ArticlePubMedGoogle Scholar
- Galati D, Bocchino M, Paiardini M, Cervasi B, Silvestri G, Piedimonte G: Cell cycle dysregulation during HIV infection: perspectives of a target based therapy. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2: 53-61. 10.2174/1568008024606284View ArticlePubMedGoogle Scholar
- Douek DC, Roederer M, Koup RA: Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60: 471-484. 10.1146/annurev.med.60.041807.123549PubMed CentralView ArticlePubMedGoogle Scholar
- Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, Chakrabarti LA: Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998, 72: 3872-3886.PubMed CentralPubMedGoogle Scholar
- Silvestri G, Sodora D, Koup R, Paiardini M, O'Neil S, McClure H, Staprans S, Feinberg M: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18: 441-452. 10.1016/S1074-7613(03)00060-8View ArticlePubMedGoogle Scholar
- Gougeon M, Ledru E, Lecoeur H, Garcia S: T cell apoptosis in HIV infection: mechanisms and relevance for AIDS pathogenesis. Results Probl Cell Differ 1998, 24: 233-248.View ArticlePubMedGoogle Scholar
- Ahr B, Robert-Hebmann V, Devaux C, Biard-Piechaczyk M: Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004, 1: 12. 10.1186/1742-4690-1-12PubMed CentralView ArticlePubMedGoogle Scholar
- Holm G, Zhang C, Gorry P, Peden K, Schols D, De Clercq E, Gabuzda D: Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol 2004, 78: 4541-4551. 10.1128/JVI.78.9.4541-4551.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Finkel T, Tudor-Williams G, Banda N, Cotton M, Curiel T, Monks C, Baba T, Ruprecht R, Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1: 129-134. 10.1038/nm0295-129View ArticlePubMedGoogle Scholar
- Igarashi T, Brown CR, Byrum RA, Nishimura Y, Endo Y, Plishka RJ, Buckler C, Buckler-White A, Miller G, Hirsch VM, Martin MA: Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous. J Virol 2002, 76: 379-391. 10.1128/JVI.76.1.379-391.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Monceaux V, Estaquier J, Fevrier M, Cumont MC, Riviere Y, Aubertin AM, Ameisen JC, Hurtrel B: Extensive apoptosis in lymphoid organs during primary SIV infection predicts rapid progression towards AIDS. AIDS 2003, 17: 1585-1596. 10.1097/00002030-200307250-00002View ArticlePubMedGoogle Scholar
- Heinkelein M, Sopper S, Jassoy C: Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells. J Virol 1995, 69: 6925-6931.PubMed CentralPubMedGoogle Scholar
- Laurent-Crawford A, Krust B, Rivière Y, Desgranges C, Muller S, Kieny M, Dauguet C, Hovanessian A: Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Res Hum Retroviruses 1993, 9: 761-773. 10.1089/aid.1993.9.761View ArticlePubMedGoogle Scholar
- Ohnimus H, Heinkelein M, Jassoy C: Apoptotic cell death upon contact of CD4+ T lymphocytes with HIV glycoprotein-expressing cells is mediated by caspases but bypasses CD95 (Fas/Apo-1) and TNF receptor 1. J Immunol 1997, 159: 5246-5252.PubMedGoogle Scholar
- Priceputu E, Rodrigue I, Chrobak P, Poudrier J, Mak TW, Hanna Z, Hu C, Kay DG, Jolicoeur P: The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice. J Virol 2005, 79: 6377-6391. 10.1128/JVI.79.10.6377-6391.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Zauli G, Gibellini D, Secchiero P, Dutartre H, Olive D, Capitani S, Collette Y: Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood 1999, 93: 1000-1010.PubMedGoogle Scholar
- Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB: Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268: 429-431. 10.1126/science.7716549View ArticlePubMedGoogle Scholar
- Purvis SF, Jacobberger JW, Sramkoski RM, Patki AH, Lederman MM: HIV type 1 Tat protein induces apoptosis and death in Jurkat cells. AIDS Res Hum Retroviruses 1995, 11: 443-450.PubMedGoogle Scholar
- Jian H, Zhao LJ: Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is subtype-dependent and potently enhanced by nonconservative changes of the leucine residue at position 64. J Biol Chem 2003, 278: 44326-44330. 10.1074/jbc.C300378200View ArticlePubMedGoogle Scholar
- Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes NN, Zhang D, Lee MD, Duvvuri U, Weiner DB: Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun 2003, 304: 583-592. 10.1016/S0006-291X(03)00631-4View ArticlePubMedGoogle Scholar
- Perfettini J, Castedo M, Roumier T, Andreau K, Nardacci R, Piacentini M, Kroemer G: Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ 2005,12(Suppl 1):916-923. 10.1038/sj.cdd.4401584View ArticlePubMedGoogle Scholar
- Perfettini J, Nardacci R, Séror C, Bourouba M, Subra F, Gros L, Manic G, Amendola A, Masdehors P, Rosselli F, et al.: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope. Cell Death Differ 2009, 16: 298-311. 10.1038/cdd.2008.158View ArticlePubMedGoogle Scholar
- Perfettini J, Nardacci R, Bourouba M, Subra F, Gros L, Séror C, Manic G, Rosselli F, Amendola A, Masdehors P, et al.: Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia. PLoS ONE 2008, 3: e2458. 10.1371/journal.pone.0002458PubMed CentralView ArticlePubMedGoogle Scholar
- Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 2000, 74: 4433-4440. 10.1128/JVI.74.9.4433-4440.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton JW, Racz P, Tenner-Racz K, Axthelm MK, et al.: Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol 2001, 75: 5646-5655. 10.1128/JVI.75.12.5646-5655.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Garg H, Joshi A, Blumenthal R: Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. AIDS Res Hum Retroviruses 2009, 25: 811-817. 10.1089/aid.2009.0010PubMed CentralView ArticlePubMedGoogle Scholar
- Garg H, Joshi A, Freed E, Blumenthal R: Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem 2007, 282: 16899-16906. 10.1074/jbc.M701701200View ArticlePubMedGoogle Scholar
- Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE: Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984, 44: 5657-5660.PubMedGoogle Scholar
- Lan P, Tonomura N, Shimizu A, Wang S, Yang YG: Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006, 108: 487-492. 10.1182/blood-2005-11-4388View ArticlePubMedGoogle Scholar
- Aquaro S, D'Arrigo R, Svicher V, Perri G, Caputo S, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, et al.: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006, 58: 714-722. 10.1093/jac/dkl306View ArticlePubMedGoogle Scholar
- Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer M, Behnke S, Frey J, Oxenius A, Joller H, et al.: Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci USA 2006, 103: 15951-15956. 10.1073/pnas.0604493103PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang L, Kovalev GI, Su L: HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007, 109: 2978-2981.PubMed CentralPubMedGoogle Scholar
- Denton PW, Garcia JV: Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 2009, 6: 13-19. 10.1007/s11904-009-0003-2PubMed CentralView ArticlePubMedGoogle Scholar
- Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV: Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008, 5: e16. 10.1371/journal.pmed.0050016PubMed CentralView ArticlePubMedGoogle Scholar
- Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, Shin HS, Brooks SF, Knight HL, Eichbaum Q, et al.: Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009, 83: 7305-7321. 10.1128/JVI.02207-08PubMed CentralView ArticlePubMedGoogle Scholar
- Leng Q, Borkow G, Weisman Z, Stein M, Kalinkovich A, Bentwich Z: Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001, 27: 389-397.View ArticlePubMedGoogle Scholar
- Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443: 350-354. 10.1038/nature05115View ArticlePubMedGoogle Scholar
- Hofer U, Schlaepfer E, Baenziger S, Nischang M, Regenass S, Schwendener R, Kempf W, Nadal D, Speck RF: Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog 6: e1000867. 10.1371/journal.ppat.1000867Google Scholar
- Melby T, Despirito M, Demasi R, Heilek G, Thommes J, Greenberg M, Graham N: Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007, 21: 2537-2539. 10.1097/QAD.0b013e3282f12362View ArticlePubMedGoogle Scholar
- Garg H, Blumenthal R: Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci 2008, 65: 3134-3144. 10.1007/s00018-008-8147-6PubMed CentralView ArticlePubMedGoogle Scholar
- Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté J: Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004, 18: 1673-1682. 10.1097/01.aids.0000131350.22032.b5View ArticlePubMedGoogle Scholar
- Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW: Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005, 79: 4991-4999. 10.1128/JVI.79.8.4991-4999.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E, Esté J: The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 1999, 13: 909-917. 10.1097/00002030-199905280-00006View ArticlePubMedGoogle Scholar
- Biard-Piechaczyk M, Robert-Hebmann V, Richard V, Roland J, Hipskind R, Devaux C: Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology 2000, 268: 329-344. 10.1006/viro.1999.0151View ArticlePubMedGoogle Scholar
- Blanco J, Barretina J, Ferri K, Jacotot E, Gutiérrez A, Armand-Ugón M, Cabrera C, Kroemer G, Clotet B, Esté J: Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. Virology 2003, 305: 318-329. 10.1006/viro.2002.1764View ArticlePubMedGoogle Scholar
- Garg H, Blumenthal R: HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006, 79: 351-362. 10.1189/jlb.0805430View ArticlePubMedGoogle Scholar
- Denizot M, Varbanov M, Espert L, Robert-Hebmann V, Sagnier S, Garcia E, Curriu M, Mamoun R, Blanco J, Biard-Piechaczyk M: HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy 2008, 4: 998-1008.View ArticlePubMedGoogle Scholar
- Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, Pereira Cda F, Saksena N, et al.: Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology 396: 246-255. 10.1016/j.virol.2009.10.029Google Scholar
- Meythaler M, Martinot A, Wang Z, Pryputniewicz S, Kasheta M, Ling B, Marx PA, O'Neil S, Kaur A: Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection. J Virol 2009, 83: 572-583. 10.1128/JVI.01715-08PubMed CentralView ArticlePubMedGoogle Scholar
- Douek D: HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007, 15: 114-117.PubMedGoogle Scholar
- Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, Teigen N, Streeck H, Stellbrink HJ, Hellman J, et al.: MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007, 81: 8180-8191. 10.1128/JVI.00421-07PubMed CentralView ArticlePubMedGoogle Scholar
- Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14: 1077-1087. 10.1038/nm.1871View ArticlePubMedGoogle Scholar
- Sterjovski J, Churchill M, Ellett A, Gray L, Roche M, Dunfee R, Purcell D, Saksena N, Wang B, Sonza S, et al.: Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4: 89. 10.1186/1742-4690-4-89PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.